361 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (860)
- Autoimmune Disorders (1)
- Blood Disorders (4)
- (-)
Cancer
(750)
- Bladder Cancer (13)
- Brain Cancer (24)
- Breast Cancer (72)
- Gastrointestinal (16)
- Gynecologic Cancer (33)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- Leukemia (79)
- Liver Cancer (11)
- Lung Cancer (65)
- Lymphoma (46)
- Multiple Myeloma (31)
- Pancreatic Cancer (22)
- Prostate Cancer (36)
- Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (44)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- COVID-19 (Coronavirus) (1)
- Diabetes (2)
- Ear, Nose and Throat (1)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (2)
- Healthy Volunteers (8)
- Liver Disease (1)
- Neurological Disorders (34)
- Obesity (1)
- Obstetrics & Gynecology (6)
- Pediatrics (42)
- Psychiatric Disorders (1)
- Surgery (1)
- Transplant (3)
- Urology (1)
Displaying 401 - 600 of 750
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
This study is being done to see how safe an investigational drug (LY3039478) is and how well it will work to help people with advanced or metastatic cancer including solid tumors or lymphoma (cancerous growth of lymphoid tissue) including chronic lymphocytic leukemia (CLL blood cell…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test any good and bad effects of the study drugs called nivolumab and ipilimumab. Nivolumab alone or with ipilimumab could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least one-…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this trial is to evaluate the safety of CB-839 in combination with nivolumab for patients with advanced/metastatic clear cell Renal Cell Carcinoma (ccRCC), melanoma, and Non-Small Cell Lung Cancer. CB-839 is a drug designed to stop cancer growth by blocking glutaminase activity.…
Condition: Cancer / Solid Tumors
Investigator: Gulam Manji, MD, PhD
Status: Closed
GSK3145095 inhibits receptor interacting protein 1 (RIP1) which may affect your immune systems response (ability to fight) to your cancer. GSK3145095 is not yet FDA approved for use in humans. This study is the first time that GSK3145095 is being given to people. This research study is being done to learn more about your…
Condition: Cancer / Gastrointestinal
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to help Arcus Biosciences, Inc. (the Sponsor) understand whether study drugs domvanalimab (also called AB154) plus zimberelimab (also called AB122) are safe and effective when given together with and without standard-of-care chemotherapy (FOLFOX) to patients with the type of cancer you have.…
Condition: Cancer / Gastrointestinal
Investigator: Ryan Moy, MD
Status: Closed
You are being invited to take part in a research study that includes studying DKN-01 combined with another investigational drug called tislelizumab and your physicians choice of a combination of drugs generally used to treat your type of cancer, either capecitabine and oxaliplatin (referred to as CAPOX) OR leucovorin calcium,…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is safe when given alone, in…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
The purpose of this study is to determine if the study drugs, encorafenib, and cetuximab, taken in combination with pembrolizumab would improve compared to the outcome of pembrolizumab alone in study patients. Encorafenib and cetuximab target cancerous BRAF proteins and potentially slow down the growth of…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
The BNT122-01 research study is testing an investigational medication (RO7198457) for patients who have had surgery for Stage II and Stage III colorectal cancer. The study will look at the safety and effectiveness of an investigational medication for patients who have had surgery for Stage II (high risk) and Stage III…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body's immune system to more effectively kill…
Condition: Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine how safe and effective the combination of atezolizumab, cobimetinib, and hydroxychloroquine is at treating KRAS-mutated advanced malignancies, and also to determine the maximum dose of this combination of drugs that can be tolerated by patients. This combination is thought to work by increasing the body's ability to…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Condition: Cancer / Gastrointestinal
Investigator: Alfred Neugut, MD, PhD
Status: Closed
Studies have shown that cancer patients may be at high risk for financial problems because of the cost of treatment. These financial problems can be stressful and sometimes might cause patients to avoid or refuse treatment. This study will measure how often financial problems happen in patients with colorectal…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this clinical trial is to evaluate safety of the trial treatment, its effects on the immune system and on urothelial cancer. The trial treatment includes INO-5401 + INO-9012 delivered by electroporation in combination with TECENTRIQ (Atezolizumab). INO-5401 + INO 9012 is a DNA based therapy that has been created…
Condition: Cancer / Pancreatic Cancer
Investigator: Paul Oberstein, MD
Status: Closed
The purpose of this study is to test whether GVAX pancreas vaccine and CRS-207 together are safe and work better than chemotherapy to treat individuals with advanced pancreatic cancer who have received at least one prior chemotherapy treatment for metastatic cancer. This study will also look at…
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to investigate how well SBP-101, the study drug, or a placebo works in combination with nap-paclixatel and gemcitabine to treat adenocarcinoma in study participants who have never received treatment for their cancer. A placebo is an inert substance that does not contain any study drug and has no…
Condition: Cancer / Brain Cancer
Investigator: Brian Gill, MD
Status: Closed
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with a placebo see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study…
Condition: Cancer
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of the study drug called atezolizumab in patients with alveolar soft part sarcoma. Atezolizumab works by unblocking your immune system, allowing your immune system cells to recognize and then attack your tumor cells. Atezolizumab could shrink your cancer but…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of the cancer immunotherapy combination treatments (CIT) combinations versus standard treatment on you and your colorectal cancer to find out which is better.
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to determine the highest dose of the study drug that can be given safely to people with certain cancers. The study will also look at how effective the study drug is in treating certain cancers. The study drug is PLX2853. The participants in this study will be the…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the intervention works in treating a specific disease. Investigational means that the intervention is being studied. The Food and Drug Administration (FDA) has approved Nivolumab as treatment for…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the drug called CB-839 HCl (telaglenastat). CB-839 HCl (telaglenastat) could shrink your cancer, but it could also cause side effects. The study doctors hope to learn if the study drug will help control the disease in patients with advanced…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, MGCD516, for the treatment of advanced liposarcoma and other soft tissue sarcomas. MGCD516 is an oral drug which blocks certain proteins on cancer cells called receptor tyrosine kinases. Receptor tyrosine kinases are proteins that help…
Condition: Cancer / Gynecologic Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to test the good and bad effects of olaparib in combination with temozolomide for the treatment of advanced uterine leiomyosarcoma (LMS). Olaparib and temozolomide could shrink your cancer, but could also cause side effects, which are described in the risks section below. The study doctors hope…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this study is to compare the effects of using Sodium Cridanimod in combination with the progestin (hormone therapy) megestrol acetate. Hormonal therapy on its own is generally not aneffective treatment for endometrial cancer when there are not have enough progestin receptors on tumor cells. The addition of the…
Condition: Cancer / Breast Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to capture and evaluate clinical data about the long-term safety and effectiveness of Novilasee - a FDA-cleared minimally invasive treatment for benign breast tumors in hopes that tracking and analyzing the safety and effectiveness of Novilase in a real world application will benefit future patients and the breast…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of the study drug in patients with Metastatic Epithelioid Hemangioendothelioma (EHE). The study drug is called trametinib. Trametinib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the…
Condition: Cancer / Prostate Cancer
Investigator: Sven Wenske, MD
Status: Closed
The goal of this study is to evaluate how the results of a novel laboratory developed and validated urine test which predicts the likelihood of high grade prostate cancer will impact the decision on whether you will have a prostate biopsy to rule out prostate cancer. Approximately 1,000 subjects…
Condition: Cancer
Investigator: Mark Heaney, MD, PhD
Status: Closed
This research study will test an investigational study drug called DCC-2618. This research study will explore the following: find the highest safe dose of DCC-2618, see how often DCC-2618 should be given, see how well research participants with cancer tolerate DCC-2618, and evaluate if DCC-2618 is effective against…
Condition: Cancer / Breast Cancer
Investigator: Jeffery Ascherman, MD
Status: Closed
The purpose of this study is to assess the performance and ease of use of the AeroDorm Tissue Expander System in women who are undergoing breast reconstruction surgery. This device is for use in women who are having or have had a mastectomy procedure to remove their breast(s) because of breast cancer (or to decrease their risk…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
The immune system can be useful in attacking cancer cells, but there are ways that the tumor can reduce or prevent the activity of the immune system. This is called immune suppression. Blocking immune suppression can allow the immune cells to attack again. There are several types of immune suppression. One example is adenosine…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drugs, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer are testing to see if SEA-CD70 is safe…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including the United States Food and Drug Administration (FDA). The study drug is…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through intravenous (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine,…
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
This study is being done to see if potential new drugs, AB680 and AB122, can be safely given in combination with chemotherapy to study patients with pancreatic cancer. The standard chemotherapy treatments that will be given in combination with AB680 and AB122 are nab-paclitaxel and gemcitabine. AB680 and AB122 are not approved…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to learn more about the safety of a cancer vaccine that teaches the immune system to recognize and possibly destroy tumor cells, and to assess how well the vaccine works. The vaccine has two components. One of them is study drug GRT-C903, and the other is GRT-C904. The vaccine works by stimulating…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
Participants are being invited to take part in a clinical research study because they have been diagnosed with locally advanced or metastatic solid tumors with mutations in the following genes: MRE11, RAD50, NBN, or CCNE1 amplification. If the participant takes part in the study, they will take an investigational drug referred to as ZN-c3 (Study Drug).…
Condition: Cancer / Brain Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to evaluate how safe the investigational drug, DSP-0390, is at different doses and to identify a recommended dose that is safe for further study. Investigational means that the study drug is currently being tested and has not been approved for use alone or in combination with any drug by the U.S. Food and Drug Administration (…
Condition: Cancer / Kidney Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
Axitinib (AG-013736) is an investigational (experimental) drug that is being studied in patients with metastatic pheochromocytoma/paraganglioma. The main goal of this study is to find out if axitinib is able to stop tumors from growing, or shrink tumors in patients with this type of cancer.
Condition: Cancer
Investigator: Susan Bates, MD
Status: Closed
This study is being done to answer the following question: Is M3814 in combination with radiation therapy and avelumab safe and tolerable in patients with advanced or metastatic cancers? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced or…
Condition: Cancer / Skin Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is determine if cemiplimab will prevent Cutaneous Squamous Cell Cancer (CSCC) from returning after surgery and radiation.
Condition: Cancer / Skin Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to determine the long-term effectiveness and safety of cemiplimab in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Condition: Cancer / Gastrointestinal
Investigator: Rachael Safyan, MD
Status: Closed
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your colorectal cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN).
Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected (surgically removed) or ablated (removed using heat) hepatocellular carcinoma (the most common type of liver cancer) who are at high risk for…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to find out if the study treatment called RO7198457 (PCV) can be safely given to patients with cancer. PCV is a personalized cancer vaccine. Participants will either received PCV alone or in combination with atezolizumab.
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
This is a research study to test a drug MK-1454 that has not been approved for sale. Pembrolizumab (MK-3475) has been approved for use in certain types of melanoma, lung cancer, and head and neck cancer however it has not been approved for lymphoma. The purpose of this study is to test the safety…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to look at whether the combination of MEDI9447 and osimertinib or MEDI9447 and AZD4635 will improve the outcome in subjects with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC).
Condition: Cancer / Gynecologic Cancer
Investigator: Ana Tergas, MD
Status: Closed
The purpose of this study, which involves research, is being done to see how well an investigational new drug and study device combination will work to treat people with pre-cancerous cells on the cervix caused by human papillomavirus (HPV). The treatment combination is testing a drug, called VGX-3100, given by injection and…
Condition: Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to assess the safety, tolerablility, and effectiveness of pembrolizumab alone or in combination with standard treatment (cisplatin and 5-fluorouracil) for recurrent or metastatic Gastric Cancer or Gastroesophageal Junction Cancer. Participants will be in the study for…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is being done to help patients diagnosed with advanced gastrointestinal stromal tumor (GIST), and treatment with imatinib has not controlled tumor growth. The purpose of this study is to see if epacadostat and pembrolizumab, will shrink cancer or stop cancer from growing.
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
This study is for patients with AML or myelodysplastic syndrome (MDS), SCLC ( other solid tumors, such as endocrine tumors or Myelofibrosis. In this research study we are going to determine how safe and well tolerated the study drug INCB059872 is in subjects/research participants with those types of cancer. Other reasons for…
Condition: Cancer
Investigator: Ojas Shah, MD
Status: Closed
The purpose of this study is to evaluate the effect and safety of MitoGel on patients with Upper TractUrothelial Carcinoma (UTUC). This research study is being done because this is a potentially beneficial new treatment for Low Grade UTUC. Mitomycin C (MMC) is FDA approved for other clinical indications and commercially available for the treatment of…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is being conducted to evaluate the performance of the AssureMDx test for the detection of bladder cancer in patients presenting with hematuria.
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have…
Study for subjects with untreated Melanoma using trial drugs Talimogene Laherparepvec and Ipilimumab
Condition: Cancer / Skin Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to find out more about talimogene laherparepvec (formerly known as OncoVEXGM-CSF), in people with advanced melanoma when given in combination with another drug called ipilimumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other…
Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to test the safety, tolerability, and anti-tumor activity of the research study drug, Pembrolizumab (also known as MK-3475) in subjects with advanced hepatocellular carcinoma (a type of liver cancer also referred to as HCC) who have taken sorafenib.
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition…
Condition: Cancer / Gastrointestinal
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to explore the effects, good or bad, of Cibisatamab, atezolizumab, obinutuzumab, and tocilizumab on patients with Colorectal cancer (CRC). In this study, you will first get treated with obinutuzumab (hereafter referred to as pretreatment with obinutuzumab). About 2 weeks later, you will then get…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This is a phase 1/1b research study for adults with a diagnosis of an advanced solid tumor for which there are no standard therapies beyond those that may have already been received. This study involves an investigational (experimental) drug called MGCD516. Investigational means that MGCD516 is not approved by the U.S. Food and Drug Administration (FDA).…
Condition: Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to determine a safe and tolerable dose of CB-839 (an investigational drug), given together with talazoparib , and if it has an effect on your type of cancer. Subjects with advanced or metastatic (spread of cancer from the primary site to other places in the body)…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the doses of RO7121661 that can be administered safely to patients and what the side effects of RO7121661 are. In addition, how RO7121661 affects your body and, in particular, your tumor will be measured. The study also aims to investigate if RO7121661 can slow down or stop the growth of tumors in patients with…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to identify the best dose of the study drugs that can be safely given to patients with cancer. The study will also evaluate how well the study drugs work in patients with cancer. The study drugs are LAG525 and PDR001. LAG525 will be given alone or in combination with…
Condition: Cancer / Pancreatic Cancer
Investigator: Susan Bates, MD
Status: Closed
The study intervention consists care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are not being treated with curative intent. The palliative care services provided to patients randomized to the intervention will be provided by board certified physicians and/or advanced practice nurses and will…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study. We invite you to participate in this research study because you have been diagnosed with Multiple Myeloma (MM). Your previous treatment(s) has/have not been successful and your cancer is progressing. The purpose of this research study is to see if selinexor (also known as KPT-330) has any effects on…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
Condition: Cancer / Skin Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to see if IMC-F106C, in combination with nivolumab, works better than the standard therapy (nivolumab alone or in combination with relatlimab) at making tumors stop growing or shrink. IMC-F106C has not yet been approved by the Food and Drug Administration (FDA). Nivolumab and the combination of nivolumab + relatlimab is FDA…
Condition: Cancer / Brain Cancer
Investigator: Aya Haggiagi, MD
Status: Closed
Phase 2, Treatment A: This study is being done to see if your recurrent brain tumor may respond to a combination of radiosurgery (a type of radiation therapy) with nivolumab (a type of immunotherapy drug). A small number of patients have already received this combination previously and have tolerated the treatment relatively well. However, we would like to…
Condition: Cancer
Investigator: June Hou, MD
Status: Closed
This research study has two parts. Participants will be enrolled in the second part of the study. The names of the study drugs are RGX-104, nivolumab, ipilimumab, docetaxel, carboplatin, and pemetrexed. The purpose of the first part of the study is to determine the highest dose of RGX-104 the body can handle. The purpose of the second part is to determine…
Condition: Cancer / Liver Cancer
Investigator: Linda Wu, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo…
Condition: Cancer / Brain Cancer
Investigator: Gurcharanjeet Kaur, MD
Status: Closed
The purpose of this study is to find out if REC-2282, an investigational new drug, is an effective and safe treatment in patients with progressive NF2 mutated meningiomas who have either NF2 disease-related meningioma or recurrent sporadic meningiomas that have NF2 mutation. Investigational new drug means a drug that has not been approved as a marketed…
Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor.…
Condition: Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to see how well an allogenic transplant works in adults with an MMUD using stem cells from a donor's blood (instead of using the donor's bone marrow). An allogeneic stem cell transplant is a standard treatment for blood cancers. An allogeneic transplant replaces your abnormal (or diseased) blood…
Condition: Cancer / Pancreatic Cancer
Investigator: Michael Kluger, MD, MPH
Status: Closed
The purpose of this study is to evaluate how safe and effective the NanoKnife System is at treating Stage 3 pancreatic adenocarcinoma. This is registry study and therefore, the NanoKnife System is not being used for study purposes. The safety and efficacy of this system will be evaluated by comparing survival rates, pain ratings, and number of adverse…
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
MS-553 is being tested for its potential to block a specific enzyme (Protein Kinase C) that is known to play a role in the growth and survival of cancer cells in different types of leukemia. The purpose of this study is to determine the safety, recommended dose and preliminary activity of MS-553 in treating CLL/SLL.
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate your immune system to attack cancer cells. Envafolimab is an experimental (investigational) …
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to test how well a smartphone application (app), called ApricityCare, allows cancer patients being treated with immune-checkpoint therapy to monitor and report side effects to their oncology nurses and doctors. The app will also provide educational material to teach patients about side…
Condition: Cancer
Investigator: Susan Bates, MD
Status: Closed
The purpose of this study is to determine whether combining the drug pembrolizumab with the standard first-line chemotherapy treatment of gemcitabine and cisplatin for biliary tract carcinoma will more effectively fight your cancer than the standard chemotherapy treatment alone. Pembrolizumab is thought to work by preventing…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to find out if you can take part in one or more of the treatment studies sponsored by Immatics. The "treatment studies" involve adoptive cellular therapy (ACT), a type of therapy in which T cells (a type of immune cell) are given to a participant to help the body fight diseases, such as cancer…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Condition: Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
This clinical trial will investigate an experimental drug called FT-2102. FT-2102 targets tumor cells that have an abnormal gene (code that tells your body what proteins to make), called isocitrate dehydrogenase 1 (IDH1). Research subjects with either a Hepatobiliary Cancer (HBC), a Chondrosarcoma, an Intrahepatic…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of study drug PLX51107 on patients with advanced malignancies such as solid tumors, lymphoma, AML or MDS. The participants in this study will be the first people to receive PLX51107. PLX51107 works by targeting and inhibiting certain activities within cells that promote tumor growth. By…
Condition: Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test the safety of the investigational study drug CB-839 when used in combination with radiation therapy and temozolomide chemotherapy. This study tests different doses of CB-839 to see which dose is safer for people. There will be up to 40 people taking part in this study. Another purpose of this study is to test magnetic…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The purpose of this study is to evaluate how accurately cells that are collected from the Fallopian tube can be categorized as benign or malignant. The MAKO 7 will be used to collect cell samples from the Fallopian tube. You are being asked to participate in the study because you are a woman who is undergoing a surgery to remove your Fallopian tubes and/or…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This is a cohort study looking at the effects of anastrozole (an aromatase inhibitor) on patients, and specifically at Aromatose Inhibitor Musculoskeletal Symptoms (AIMSS). The genetic predictors of AIMSS will also be evaluated. Participants will take daily anastrazole and will be followed for 12 months. The study will enroll 35 patients at Columbia…
Condition: Cancer
Investigator: Changchun Deng, MD, PhD
Status: Closed
The purpose of the study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572 when taken with a drug to help the white blood cells in your blood (a drug called granulocyte colony-stimulating factor or G-CSF) in an intermittent or continuous once-daily dosing schedule in subjects with advanced cancer…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of the Main study is to test the overall effects of E7777 on you and your illness. It is not known what effect E7777 will have on your illness or what the side effects will be. This study will look at the effect E7777 has on your body and your disease. It will also look at how your body absorbs, distributes, breaks down, and gets rid of the…
Condition: Cancer
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat Monoclonal Gammopathy of Renal…
Condition: Cancer
Investigator: Joseph Jurcic, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with Polycythemia Vera (PV) that requires you to have phlebotomies (blood draws from a vein) to control your symptoms. This type of PV is called Phlebotomy-Dependent Polycythemia Vera (PD-PV). This clinical study is testing a new study treatment for this medical condition. The…
Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
The purpose of this study is to assess the effectiveness of the therapy to be administered (how well it works) and the safety profile (if it has any unwanted effects on you that you can feel or on laboratory tests that are obtained) of lanreotide (a somatostatin analog (a hormone produced by the hypothalamus and some other tissues such as the pancreas and…
Condition: Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. Not all patients will get the same dose of the study drug. At the beginning of the study, a small group of three to six patients will receive an infusion with a low dose of the study drug. If this dose does not cause…
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of the experimental drug BGB-3111, versus a known standard treatment called bendamustine plus rituximab (B+R) on you and your chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to find out which is better. In this study, you will receive either BGB-3111 or the standard…
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (ages 18-21)
Condition: Cancer
Investigator: Luca Szalontay, MD
Status: Closed
The purpose of this study is to find out the effects and safety of an investigational (experimental) new drug called copanlisib in pediatric patients from 6 months to 21 years of age. This study consists in two-phase, Phase I part will determine which is the right dose of copanlisib to be used in children/adolescents/adults with relapsed (has returned) or…
Condition: Cancer
Investigator: Markus Mapara, MD
Status: Closed
The purpose of this study is to find out what effects (good and bad) an investigational (not approved by the Food and Drug Administration) drug, RGI-2001 has on you and graft-versus-host disease (GVHD). GVHD is a side effect of blood or bone marrow stem cell transplant that sometimes can be deadly. This study is trying to see if the experimental drug, RGI-…
Condition: Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of the study is to evaluate the tolerability of a ketogenic diet in conjunction with metformin in people with malignant glioma. The study doctors will try to determine if maintaining the ketogenic diet with metformin will have any effect on your tumor.
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the overall study is to learn if it is safe to give genetically changed T cells (IMA202) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with melanoma solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out how safe study drug olaratumab given with gemcitabine and docetaxel is for patients and whether olaratumab given with gemcitabine and docetaxel can help patients with advanced or metastatic soft tissue sarcoma (STS).
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The main purpose of this study is to learn more about the study drug called LY3321367. The study wants to know more about the following: The safety of LY3321367 alone and in combination with another drug called LY3300054 and any side effects you might have Whether LY3321367 is tolerable when taken alone and in combination with LY3300054. How much…
Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
You are being asked to participate in this study because you have a neuroendocrine tumor that has spread to your organs. You may or may not have had prior treatment for your neuroendocrine tumor. The purpose of this study is to determine if a drug called entinostat has efficacy in shrinking neuroendocrine tumors. People who usually have metastatic…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
This study is for patients with metastatic or locally advanced soft tissue sarcoma (STS) who are not amenable to treatment with surgery or radiotherapy with curative intent. Patients will be treated with doxorubicin plus olaratumab versus doxorubicin plus placebo intravenously for 8 cycles. Patients without disease progression will be allowed to continue…
Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
Aim 1: To describe the perceptions and experiences of CIPN by patients. 1. To describe the terminology used by patients to describe CIPN.; 2. To describe the effects that CIPN has on patients' day-to-day quality of life.; 3. To describe how patients communicate with their healthcare providers about CIPN, and what barriers may interfere with this…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This study is for subjects with either cancer of the head and neck, lung cancer or colorectal cancer. The aim of this research study is to identify the best dose of an experimental drug called MEDI1873 and to see if it is safe and tolerable in subjects with advanced…
Condition: Cancer
Investigator: Mark Heaney, MD, PhD
Status: Closed
This research study is a 3-part, randomized, double-blind study designed to learn more about the safety and effectiveness of an experimental drug called avapritinib (formerly called BLU-285), when given to individuals who have been diagnosed with Indolent Systemic Mastocytosis (ISM) or Smoldering Systemic Mastocytosis (SSM). Experimental means it is not yet…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to learn more about the study drug, MIW815 (ADU-S100). The study will identify the dose that can safely be given to people with solid tumors or lymphomas. The study will also see how well MIW815 (ADU-S100) works in people treated.
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with the following types of cancer: Triple negative breast cancer, non-small cell lung cancer, mesothelioma, renal cell carcinoma, melanoma, head and and neck squamous cell carcinoma, colorectal cancer,…
Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to determine if denosumab treatment affects the rate of growth of the cells in the ends of the fallopian tubes compared to receiving no treatment in premenopausal BRCA1/2 mutation carriers.
Condition: Cancer
Investigator: Alice Lee, MD
Status: Closed
The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United…
Condition: Cancer
Investigator: Thomas Brannagan, MD
Status: Closed
The primary purpose of this research study is to better understand what causes chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy is a numbness, tingling, or pain caused by chemotherapy. It can interfere with activities of daily life and quality of life to different degrees.
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to find out if the study drug zanubrutinib is safe and can help subjects who have Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This will involve comparison of two drugs, zanubrutinib and ibrutinib, in treating CLL/SLL by: (1)Testing how effectively the drug zanubrutinib controls CLL/SLL and (2)…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see how teclistamab by itself compares to study treatment combinations that are commonly used to treat multiple myeloma. These study treatment combinations are either pomalidomide, bortezomib and dexamethasone (called PVd) or carfilzomib and dexamethasone (called Kd). The patients will be randomly assigned to one of the study…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that is used to…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA-approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
This study is being done to determine if a study drug called lenalidomide can be combined with full doses of EPOCH chemotherapy for patients with Adult T-Cell Leukemia-Lymphoma (ATLL), and to define the highest dose and longest duration of lenalidomide that can be given safely in combination with EPOCH. EPOCH chemotherapy is a combination of five…
Condition: Skin Cancer / Melanoma
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to identify the safest and most tolerable dose of the study drug, DYP688 that can be given to patients. Also to evaluate how well DYP688 might work in treating certain types of cancer including metastatic uveal melanoma and other melanomas with GNAQ/11 mutations (or genetic changes to the gene GNAQ…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called study drug) in participants…
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This study will utilize an investigational drug combination (also known as the study drugs) called relatlimab and nivolumab as a possible treatment for recurrent/relapsed (returned) or refractory (treatment-resistant) cHL and NHL. An investigational drug combination is one that has not been approved by regulatory agencies, such as the United States (US)…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is assess the safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis. Furthermore, the purpose of phase 2 part of this study is to compare the effectiveness of venetoclax and…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Avelumab is a drug that works by triggering the immune system so it can try to attack the cancer again. Avelumab works in a similar way to cemiplimab, which is the usual…
Condition: Cancer / Solid Tumors
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target …
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06650808, when given as a single agent and to find the best dose for treating cancer. Prior to this study, PF-06650808 has never been given to people. PF-06650808 is known as an antibody drug conjugate. A toxic agent is…
Condition: Cancer / Lymphoma
Investigator: Andrew Lipsky, MD
Status: Closed
This research study is being done to test the effectiveness and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The experimental drug called INBRX 109 has been developed as a treatment for unresectable or metastatic conventional chondrosarcoma. The purpose of this study is to learn about the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective…
Condition: Cancer / Sarcoma
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test what dose of BPX-601 can be given safely with rimiducid to patients with certain types of cancer. The study will look for side effects (good and bad) and how your body responds to the treatment. The study will also see if the treatment helps to stop your cancer…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for adult subjects with head and neck cancer (oral cavity, oropharynx middle part of the throat, hypopharynx bottom part of the throat, or larynx part of throat between the base of the tongue and the windpipe) that has either returned after treatment (recurrent) or is newly diagnosed. If newly diagnosed, the…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
This is a Phase 2-3 study evaluating the effects of selinexor in patients with advanced unresectable dedifferentiated liposarcoma (DDLS). This study drug selinexor works by trapping tumor suppressing proteins within the nucleus of the cells and thus causing the cancer cells to die or stop growing. Selinexor has previously been…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The main goal of this study is to find out about how duvelisib acts in patients with CLL/SLL who were previously treated with a BTKi (Bruton Tyrosine Kinase inhibitor - commercially available ibrutinib or another investigational BTKi). Duvelisib is an investigational drug, meaning that it is not FDA approved, designed to try to stop…
Condition: Cancer / Gastrointestinal
Investigator: Matthew Ingham, MD
Status: Closed
Deciphera Pharmaceuticals, LLC., the Sponsor of this study, is developing a drug called DCC-2618 to treat Gastrointestinal Stromal Tumors (GIST) that are growing because of changes in specific genes. Genes are the instructions that tell a part of your body called a cell what to do. Cancer changes the genes so that the…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this part of the study is to obtain further information about the safety and effectiveness(how well it works) of azacitidine plus birinapant (the investigational drug), in people with higher-risk myelodysplastic syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMMoL). One of the standard drugs for these diseases is azacitidine which all…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to see if the combination of fianlimab (REGN3767) and cemiplimab (REGN2810) is an effective treatment compared to pembrolizumab in participants that have had melanoma removal surgery but are still at high risk for the return of the disease. This study involves 2 study drugs: fianlimab (REGN3767) and cemiplimab (REGN2810). The…
Condition: Cancer / Sarcoma
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to test the good and bad effects of the drugs called belinostat and SGI-110 (guadecitabine). These drugs could shrink your cancer, but they could also cause side effects. The study doctors hope to learn if the study drugs will shrink the cancer more often than…
Condition: Cancer / Solid Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of the study is to test the following: 1) The safety and tolerability (how you feel when you take the drug) of the study drug, 2) The pharmacokinetics (PK) (how the study drug is absorbed within your body, spread throughout your body, and eliminated from your body) of the study drug, 3) The pharmacodynamics (PD) (how the study drug affects…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR19B to treat certain types of cancers. PBCAR19B is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR269A to treat certain types of cancers. PBCAR269A is a new investigational treatment for certain types of cancer of the blood, such as multiple myeloma. It is made from a type of blood cells known…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to test the safety, anti-tumor activity, and the ability of a new investigational drug called BMS-986179 (also known as anti-CD73) plus nivolumab (also known as BMS-936558) to block the protein CD73 from producing high amounts of a product known as adenosine which blocks your immune system from killing your…
Condition: Cancer / Solid Tumors
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to find a safe dose of JNJ-63898081 that can be used for further studies in subjects with advanced cancers such as metastatic castration resistant prostate cancer (mCRPC) or metastatic kidney cancer, also referred to as renal cell…
Condition: Cancer / Solid Tumors
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab (Arm A of the study). Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the growth of cancer…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is research study for patients who have been newly diagnosed with Multiple Myeloma (MM). Their previous treatments have not been successful and their cancer is progressing. The purpose of this research study is to see if the study drug selinexor (KPT-330) has any effects against their cancer…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR20A to treat certain types of cancers. PBCAR20A is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose…
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Currently Recruiting
You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you,…
Study of Daratumumab in Addition to Chemotherapy for Patients with Smoldering Multiple Myeloma (SMM)
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period…
Condition: Cancer / Leukemia
Investigator: Andrew Lipsky, MD
Status: Currently Recruiting
This research is being done because Richter's transformation, which is a life-threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone,…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1)…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm),…
Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm),…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Currently Recruiting
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to test whether BMS-986393 in combination with other anti-cancer drugs is safe and effective at treating people with multiple myeloma (MM) that has come back after previous treatment (relapsed) or is not responding to current treatment (refractory). The researchers think that the combinations of…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
This research study mainly aims to test the safety and tolerability of AGEN1181 and balstilimab and to determine the most appropriate dose of the study drug AGEN1181 alone and in combination with balstilimab. AGEN1181 targets cells that are a part of the body's immune system to block a protein called cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
This study is being done to answer the following questions: Will patients that are 75 years of age or older who were recently diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
You are being invited to take part in a research study that includes studying an experimental treatment named axicabtagene ciloleucel, referred to as axi-cel. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while…
Condition: Cancer / Sarcoma
Investigator: Prabhjot Mundi, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This investigational drug is being studied in unresectable or metastatic, relapsed, or refractory leiomyosarcoma along with Dacarbazine. Dacarbazine is a drug that is FDA-approved for the treatment of other types of cancer…
Condition: Cancer / Sarcoma
Investigator: Shaheer Khan, DO
Status: Closed
The study drug, CFT8634, is an investigational therapy that has been shown in animal studies to help break down the BRD9 protein, an important protein in the body that helps SMARCB-null tumors, such as your own, to grow. CFT8634 is able to do so by using the body's own protein-recycling equipment. (In short, your cells are capable of breaking down proteins…
Condition: Cancer / Sarcoma
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerated dose of the study drug will be determined. In the phase II portion,…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a blood cancer called Acute Myeloid Leukemia (AML) with or suspected to have a specific gene mutation (TP53 mutation) for which you have not received any prior AML treatment. Tumor protein p53 (TP53) is a gene that codes for a tumor…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Closed
You are being asked to participate in this study because you have multiple myeloma that has either returned after your most recent treatment regimen or has not responded to your most recent treatment regimen. Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help…
Condition: Cancer / Sarcoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of stress response proteins. These interactions are thought to be important for…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This research study is evaluating an investigational drug, called cirmtuzumab, in combination with astandard drug, called ibrutinib (Imbruvica), as a possible treatment for patients with CLL/SLL or MCL. All cells in the body receive signals to grow and survive, but sometimes these signals get out of control, causing too much cell growth. When the growth of…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find the highest dose and the best schedule of the study drug, DS-3032b, that can be given safely in subjects with advanced solid tumors and for subjects that did not respond or no longer respond to standard therapy. DS-3032b works against cancer by blocking the activity of a protein called MDM2…
Condition: Cancer / Solid Tumors
Investigator: Gulam Manji, MD, PhD
Status: Closed
This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to gather information on the safety of TH-302 and its effect on your cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about your specific cancer such as the…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This is a Phase 1 multiple dose, dose escalation trial in patients with advanced solid tumors who have failed or cannot tolerate standard therapies. Your study doctor has determined that you have an advanced cancer (solid tumor). You are invited to take part in this research study. This study has two parts. In Part 1, the…
Study of sertraline (Zoloft) with ara-C in combination in patients with acute myeloid leukemia (AML)
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of the study is to evaluate the safety, tolerability (the effect of the drug on your body), pharmacokinetics (the effect of your body on the drug) and maximum tolerated dose of sertraline in combination with cytosine arabinoside (ara-C, cytarabine) when given to patients with treatment-resistant myeloid leukemia. In addition, the effect of the…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). This study will test the safety of an experimental anti-cancer drug (MEDI4736). MEDI4736 is an antibody (a protein produced by the defense system of the body immune system) that has been made in the laboratory.…
Condition: Cancer / Leukemia
Investigator: Alice Lee, MD
Status: Closed
This study is for children and teens who have been diagnosed with Acute Myeloid Leukemia (AML). AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
The purpose of this study is to compare the combination of brentuximab vedotin and nivolumab to the combination of brentuximab vedotin, nivolumab, and ipilimumab. Both brentuximab vedotin and nivolumab are FDA-approved as single drugs for patients who have relapsed or refractory Hodgkins lymphoma. The combination of these drugs together, and with ipilimumab…
Condition: Cancer / Solid Tumors
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to establish the safety profile of the study drug HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. HuMax-AXL-ADC binds to a specific antigen called Axl, which is expressed on the tumor cells in the cancer types treated in this trial. When the trial drug binds to the…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This research study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in subjects with untreated multiple myeloma. This comparison will include how many subjects respond to each study treatment combination, how long…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (like people who have had a transplant and must be on medications that suppress their immune system), EBV can cause certain diseases…
Condition: Cancer / Lymphoma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to compare the usual treatment alone to using venetoclax plus the usual treatment. The addition of venetoclax to the usual treatment could shrink the cancer. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better than the usual…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
This study will look at the safety of a drug (REGN5458) in patients with multiple myeloma. It will also try to find out what the best dose of REGN5458 is and look for any signs that REGN5458 can help treat your cancer. REGN5458 is investigational, which means it has not been approved by the US Food and Drug Administration (FDA…
Condition: Cancer / Lymphoma
Investigator: Fabio Iwamoto, MD
Status: Closed
In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses…
Condition: Cancer / Leukemia
Investigator: Nobuko Hijiya, MD
Status: Closed
The purpose of this study is to find out if the drugs called Nivolumab and 5-Azacytidine can be given safely in children and young adults with Acute Myeloid Leukemia (AML) which has come back after treatment or has not responded to standard therapy. These drugs are thought to work by turning on genes that limit the growth of cancer…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
TAK-007 is being developed as a possible treatment for Lymphoma. TAK-007 is a cell therapy, which means that it consists of live cells that have been modified to help your body to fight Lymphoma. The use of TAK-007 in this study is experimental. Fresh (unfrozen) CAR NK cells, similar to TAK-007, are being tested in another study. In this study, frozen TAK-…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to determine the safety and efficacy of CMP-001 when given in combination with nivolumab for patients with unresectable (not capable of being surgically removed) or metastatic (cancer spreads to a different body part from where it started) melanoma. CMP-001 will be given as an injection into the…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to test the study drug ALKS 4230 to see how well the drug works on patients with advanced cutaneous melanoma or subjects with advanced mucosal melanoma and have received prior treatment with an anti-programmed death-ligand 1 (anti-PD-L1) therapy, and your cancer has spread. This study will explore…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated,…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated,…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
The purpose of the study is to test the safety of an investigational study drug called BMS-986218 (also known as Anti-CTLA4-NF monoclonal antibody) administered alone and in combination with nivolumab, and in comparison to Ipilimumab. This study will investigate how research subjects with advanced solid tumors tolerate these drugs and identify the highest…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to determine the effectiveness of the study treatment- bendamustine and rituximab (BR) followed by venetoclax for 12 months. The combination of the drugs bendamustine and rituximab is a commonly used treatment for your disease. Venetoclax is an oral drug that blocks a protein called BCL-2 which is present on CLL cells. With this…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the study drug, BI 907828 for safety, effectiveness, and side effects when compared to receiving the standard treatment, doxorubicin, in subjects with dedifferentiated liposarcoma (DDLPS). BI 907828 has proven to minimize a critical protein interaction between MDM2 and p53, two proteins in your body, which when their…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
Patients who will be receiving immune effector cell (IEC) therapy for the treatment of their cancer (leukemia) are being asked to participate in this study. IEC can produce a harmful side effect called Cytokine Release Syndrome (CRS). CRS involves a release of a large amount of proteins into the bloodstream. This may cause…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia (AML). Also, the study plans to determine the maximum tolerated dose (highest safe dose) of CYNK-001 and assess whether CYNK-001 can eliminate your residual (leftover) disease.…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE